Dr. Moises R. Cossio, D.O.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 326
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
VA license 0102201314 -
Critical Care Medicine (Internal Medicine) Physician
VA license 0102201314 -
Internal Medicine Physician
VA license 0102201314
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carilion Medical Center Roanoke, VA
- Carilion New River Valley Medical Center Christiansburg, VA
- Carilion Franklin Memorial Hospital Rocky Mount, VA
Medical groups
- Carilion Medical Center (977 clinicians)
- Carilion Healthcare Corporation (536 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 326
- Services billed
- 729
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 253 | 110 |
| Established patient office or other outpatient visit, 30-39 minutes | 111 | 90 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 88 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 65 | 52 |
| Test to examine how well the lungs exchange gases | 52 | 52 |
| Established patient office or other outpatient visit, 40-54 minutes | 46 | 44 |
| Test to determine lung volumes using sensors | 42 | 42 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | 41 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Roanoke, VA | 230 |
| Furosemide Other prescribers in Roanoke, VA | 169 |
| Opsumit (macitentan) | 148 |
| Jardiance (empagliflozin) Other prescribers in Roanoke, VA | 137 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Roanoke, VA | 108 |
| Tyvaso Dpi (treprostinil) | 102 |
| Spironolactone Other prescribers in Roanoke, VA | 88 |
| Adempas (riociguat) | 86 |
| Sildenafil Citrate Other prescribers in Roanoke, VA | 86 |
| Prednisone Other prescribers in Roanoke, VA | 75 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 16 payments worth $1,035 in total to this clinician.
| United Therapeutics Corporation | $545 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $218 |
| Abiomed | $136 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $77.32 |
| Liquidia Technologies, Inc. | $58.94 |
| Food and Beverage | $971 |
|---|---|
| Education | $63.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. May 7, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $63.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $41,488 in research payments for these studies, mostly to the institutions running them.
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.